Mepsevii Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Mepsevii market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth during the historical period can be attributed to a heightened focus on personalized medicine, rising healthcare spending, increasing awareness of rare genetic disorders, growing awareness among healthcare providers, and a supportive regulatory environment.

Market growth during the forecast period can be driven by factors such as an increase in the number of clinical trials, rising prevalence of rare disorders, growing popularity of stem cell therapies, increasing cases of mucopolysaccharidosis, and the rising use of novel treatment modalities. Key trends in the forecast period include the development of therapies for rare diseases, advancements in medical technologies, innovations in telemedicine, new drug delivery methods, and the development and wider availability of advanced treatment options.

The rising number of mucopolysaccharidosis disorders is expected to drive the growth of the mepsevii market in the future. Mucopolysaccharidosis (MPS) disorders are a group of genetic diseases caused by the deficiency of specific enzymes that prevent the breakdown of glycosaminoglycans, leading to their accumulation in various organs and causing progressive damage. The increase in MPS cases can be attributed to improved diagnostic methods, greater awareness among healthcare providers, and better access to genetic testing, resulting in earlier and more accurate identification of the disease. Mepsevii helps treat mucopolysaccharidosis VII (MPS VII) by providing enzyme replacement therapy that replenishes the missing enzyme, beta-glucuronidase. This treatment helps reduce the harmful accumulation of specific sugars in the body, alleviates symptoms, and slows disease progression. For example, in February 2022, Medscape, a US-based website providing medical information and continuing education, reported that the global prevalence of all types of MPS is estimated to be 1 in every 16,000 to 30,000 births. Therefore, the rising incidence of mucopolysaccharidosis disorders is fueling the growth of the mepsevii market.

A key trend in the mepsevii market is the development of innovative therapies, such as replacement therapy, to address the genetic causes of mucopolysaccharidosis VII and improve patient outcomes. Replacement therapy is a medical treatment that supplies a substance the body lacks or cannot produce in adequate amounts. This approach is used for hormone imbalances, enzyme deficiencies, or organ dysfunction. For example, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, announced that Mepsevii (vestronidase alfa) enzyme replacement therapy has received reimbursement approval in Spain for treating mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. This approval is a significant step in expanding access to treatment for patients in Spain with this rare and life-threatening genetic disorder, which affects the body's ability to break down certain sugars, leading to the accumulation of harmful substances in the body.

In December 2024, Cerity Partners LLC, a US-based capital markets company, acquired Ultragenyx Pharmaceutical Inc. for approximately $1.773 million. Through this acquisition, Cerity Partners LLC obtained 31,919 shares of Ultragenyx, aiming to enhance its investment portfolio by expanding into the biotechnology sector, with a focus on companies specializing in rare diseases. Ultragenyx Pharmaceutical Inc. is a US-based biotech company that developed Mepsevii as part of its portfolio of treatments for rare genetic conditions.

The key company operating in the mepsevii market is Ultragenyx Pharmaceutical Inc.

North America was the largest region in the mepsevii market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mepsevii report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mepsevii market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mepsevii (vestronidase alfa) is an enzyme replacement therapy approved for the treatment of Mucopolysaccharidosis VII (MPS VII), a rare genetic condition. It works by replacing the deficient enzyme beta-glucuronidase, helping to break down harmful substances in the body. The treatment is aimed at improving symptoms and enhancing the quality of life for patients with MPS VII.

The primary formulations of mepsevii are intravenous infusion and pre-filled syringes. Intravenous infusion is a medical procedure where fluids, medications, or nutrients are delivered directly into the bloodstream through a vein. This method is commonly used to administer mepsevii, ensuring the drug reaches the bloodstream efficiently to achieve optimal therapeutic effects. It is used for various indications, including mucopolysaccharidosis VII (MPS VII, sly syndrome). The drug is distributed through hospitals, specialty clinics, home healthcare services, and pharmacies, and is utilized by end users, including both pediatric and adult patients.

The mepsevii market research report is one of a series of new reports that provides mepsevii market statistics, including the mepsevii industry's global market size, regional shares, competitors with a mepsevii market share, detailed mepsevii market segments, market trends and opportunities, and any further data you may need to thrive in the mepsevii industry. This mepsevii market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mepsevii market consists of sales of mepsevii (vestronidase alfa-vjbk). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.